A mutation in JAK2 (Val617Phe), a key member of the cytokine intracellular signaling pathway, can be found in 90–95% of patients with polycythemia vera.
Many of those without this particular JAK2 mutation have mutations in exon 12.
This instigates a stem cell disorder.